HS Pharma holds a family of proprietary intellectual property and licensed technology from the Medical Research Council (UK) in the field of oncology.

We are committed to continuing the Medical Research Council's promising research and development efforts surrounding silica nanoclusters and their inducement of T-Cell activation through direct ligation of the T-Cell receptor complex.